BR112012027886A2 - método e composição de peptídeo terapêutico - Google Patents

método e composição de peptídeo terapêutico

Info

Publication number
BR112012027886A2
BR112012027886A2 BR112012027886A BR112012027886A BR112012027886A2 BR 112012027886 A2 BR112012027886 A2 BR 112012027886A2 BR 112012027886 A BR112012027886 A BR 112012027886A BR 112012027886 A BR112012027886 A BR 112012027886A BR 112012027886 A2 BR112012027886 A2 BR 112012027886A2
Authority
BR
Brazil
Prior art keywords
therapeutic peptide
composition
therapeutic
dimethylamino
propionate
Prior art date
Application number
BR112012027886A
Other languages
English (en)
Inventor
Bassam B Damaj
Richard Martin
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of BR112012027886A2 publication Critical patent/BR112012027886A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

método e composição de peptídeo terapêutico. composições de peptídeo terapêutico compreendem um peptídeo terapêutico, como insulina, juntamente com um alquil n, amino acetato n-dissubstituído, como dodecil 2-(n,n-dimetilamino) propionato.
BR112012027886A 2010-05-04 2011-05-04 método e composição de peptídeo terapêutico BR112012027886A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34381510P 2010-05-04 2010-05-04
PCT/US2011/000790 WO2011139370A1 (en) 2010-05-04 2011-05-04 Therapeutic peptide composition and method

Publications (1)

Publication Number Publication Date
BR112012027886A2 true BR112012027886A2 (pt) 2016-08-09

Family

ID=44903936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027886A BR112012027886A2 (pt) 2010-05-04 2011-05-04 método e composição de peptídeo terapêutico

Country Status (16)

Country Link
US (2) US20130209393A1 (pt)
EP (1) EP2566503A4 (pt)
JP (1) JP2013528587A (pt)
KR (1) KR20130067266A (pt)
CN (1) CN102858364A (pt)
AU (1) AU2011249040B2 (pt)
BR (1) BR112012027886A2 (pt)
CA (1) CA2797966A1 (pt)
CR (1) CR20130006A (pt)
IL (1) IL222425A0 (pt)
MX (1) MX336037B (pt)
NZ (1) NZ603091A (pt)
RU (1) RU2012153175A (pt)
SG (2) SG186300A1 (pt)
WO (1) WO2011139370A1 (pt)
ZA (1) ZA201209021B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082866A (en) * 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
EP1100522B1 (en) * 1998-07-27 2016-12-07 Emisphere Technologies, Inc. Pulmonary delivery of active agents
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
JP4540667B2 (ja) * 2003-03-21 2010-09-08 ネクスメツド・ホールデイングス・インコーポレイテツド 抗真菌性ネイルコート
EP1663142A2 (en) * 2003-06-23 2006-06-07 MacroChem Corporation Compositons and methods for topical administration
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
WO2012097160A1 (en) * 2011-01-14 2012-07-19 Nexmed Holdings, Inc. Rectal delivery method for therapeutic peptides

Also Published As

Publication number Publication date
WO2011139370A1 (en) 2011-11-10
IL222425A0 (en) 2012-12-31
CN102858364A (zh) 2013-01-02
EP2566503A4 (en) 2013-10-02
AU2011249040A1 (en) 2012-11-08
KR20130067266A (ko) 2013-06-21
MX336037B (es) 2016-01-07
US20130209393A1 (en) 2013-08-15
SG10201600228QA (en) 2016-03-30
ZA201209021B (en) 2013-09-25
MX2012012823A (es) 2013-03-05
SG186300A1 (en) 2013-01-30
EP2566503A1 (en) 2013-03-13
NZ603091A (en) 2014-10-31
RU2012153175A (ru) 2014-06-20
JP2013528587A (ja) 2013-07-11
CR20130006A (es) 2013-06-27
US20150265709A1 (en) 2015-09-24
AU2011249040B2 (en) 2014-05-15
CA2797966A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
IL254879B (en) History of dolastatin associated with unnatural amino acids and pharmaceutical preparations containing them
IL229353B (en) Dolestatin derivatives related to unnatural amino acids and medicinal preparations that include them
UA109924C2 (uk) Аміди аміноінданів, які мають високу фунгіцидну активність та їх фітосанітарна композиція
CL2015001695A1 (es) Una composicion de dos componentes para entregar zinc a un cuerpo comprendiendo (i) un primer componente de un complejo de halogenuro de zinc y (aminoacido o trialquilglicina) y (ii) un segundo componente de cisteina, en donde el primer y segundo componente se mantienen separados uno del otro hasta que se dispensan y se combinan para aplicarse al cuerpo, util para el cuidado oral y personal.
BR112015002698A2 (pt) distribuidor de material volátil e método de emissão de um material volátil
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
BR112015014253A2 (pt) produtos de higiene bucal que compreendem um complexo de haleto de aminoácido e zinco tetrabásico
BR112013011868A2 (pt) compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos
DK3130347T3 (da) PH20-polypeptidvarianter, formuleringer og anvendelser deraf
EA201391489A1 (ru) Композиции со сниженной вязкостью
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
UA118167C2 (uk) Пептид та його застосування
TR201905683T4 (tr) Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem.
BR112013033464A2 (pt) composto, acetato, composição farmacêutica, combinação farmacêutica, método e método melhorado
TN2012000415A1 (en) Pharmaceutical composition comprising a pyrimidineone derivative
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
CL2013000069A1 (es) Compuestos derivados de heterociclos fusionados, moduladores s1p; composicion farmaceutica; y uso en enfermedades neurodegenerativas.
BR112014002845A2 (pt) “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
EP2782926A4 (en) PEPTIDE SEQUENCE DESIGN AND USE THEREOF FOR PEPTIDE-RELATED SIRNA DELIVERY
EP3362048A4 (en) COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS
BR112013024265A2 (pt) peptídeo cíclico, uso de peptídeos cíclicos, método para o tratamento de doenças, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]